文献速递肾小球疾病慢性肾脏病

口服骨化三醇对接受RAS阻断剂的IgA肾病患者的附加肾脏保护作用

Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

这项双盲安慰剂对照试验纳入138例活检确诊、已最大剂量使用RAS阻断剂后仍有持续蛋白尿(0.5-3.5 g/天)的IgA肾病患者,随机接受0.25 μg/天骨化三醇或安慰剂治疗12个月。骨化三醇组UPCR和尿白蛋白肌酐比的下降幅度均显著大于安慰剂组,且eGFR年下降斜率更小,不良事件与安慰剂相当。

要点

  • 骨化三醇0.25 μg/天可显著降低IgA肾病患者残余蛋白尿。
  • 骨化三醇组eGFR年下降幅度小于安慰剂组,提示延缓肾功能下降。
  • 不良事件与安慰剂相当,安全性可接受。

核心结论

  • 在已最大剂量使用RAS阻断剂的IgA肾病患者中,加用0.25 μg/天骨化三醇可安全降低残余蛋白尿并减缓eGFR下降。
  • 提示骨化三醇在该人群中有潜在治疗作用。

研究设计与样本

  • 双盲、安慰剂对照试验,纳入活检确诊的IgA肾病患者。
  • 入组条件为最大剂量使用RAS阻断剂后仍有持续蛋白尿0.5-3.5 g/天。
  • 共138例来自六家医疗中心,随机分配至安慰剂组(n=69)或骨化三醇0.25 μg/天组(n=69),治疗12个月。
  • 115例(83.3%)完成研究。
  • 主要结局为治疗期间平均尿蛋白肌酐比(UPCR)和每日尿蛋白排泄量的变化。

主要发现

  • 不良事件两组相当。

临床怎么用

  • 对已最大剂量使用RAS阻断剂但仍有残余蛋白尿的IgA肾病患者,可考虑加用0.25 μg/天骨化三醇以进一步降低蛋白尿并延缓eGFR下降。
  • 用药期间需监测不良事件,本研究显示与安慰剂相当。

局限性

  • 研究仅纳入蛋白尿0.5-3.5 g/天的患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with immunoglobulin A nephropathy (IgAN) and moderate proteinuria are at risk of progressive renal failure despite the maximal use of renin-angiotensin system blockers (RASBs). This study evaluated the efficacy of active vitamin D in reducing proteinuria in patients with IgAN receiving RASBs. METHODS: In this double-blind, placebo-controlled trial, we enrolled biopsy-confirmed patients with IgAN and persistent proteinuria (0.5-3.5 g/day) after maximal use of RASBs. Patients were randomized to receive either 0.25 μg/day of calcitriol or placebo for 12 months. The primary outcomes were the change in the mean urinary protein:creatinine ratio (UPCR) and daily urinary protein excretion during the treatment. RESULTS: A total of 138 patients from six medical centres were enrolled and assigned to receive a placebo (n = 69) or 0.25 μg of calcitriol (n = 69) and 115 patients (83.3%) completed the study. The calcitriol group showed a greater reduction in geometric means of UPCR {mean difference -187 mg/g [95% confidence interval (CI) -370.6 to -4.0], P = .04} and urinary albumin:creatinine ratio [-162 mg/g (95% CI -290.9 to -34.6), P = .01] than placebo. Changes in daily urinary protein excretion were -3.5% (from 1.32 to 1.02 g/day) in the control group and -13.1% (from 1.29 to 0.97 g/day) in the calcitriol group, without any statistically significant differences (P = .11). The annual decrease of the estimated glomerular filtration rate (eGFR) was -0.32 ml/min/1.73 m2 (95% CI -2.54 to 1.99) in the calcitriol group and -3.64 ml/min/1.73 m2 (95% CI -5.70 to -1.58) in the placebo group (calcitriol versus placebo over time, P = .02). Adverse events were comparable between the groups. CONCLUSION: The addition of 0.25 μg/day calcitriol to RASBs safely lowered residual proteinuria and slowed the eGFR decline in patients with IgAN, suggesting a potential therapeutic role for calcitriol in this population.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Joo YS, Chang TI, Kim DK, et al. Additive renoprotective effects of oral calcitriol on patients with IgA nephropathy receiving RAS blockers. Nephrol Dial Transplant. 2026. PMID: 41178795. doi:10.1093/ndt/gfaf187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。